Nkure Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$740K
- Investors
-
5
Nkure Therapeutics General Information
Description
Developer of anticancer immunotherapies designed to provide affordable natural killer cell-based therapies. The company offers therapies effective against leukemia, multiple myeloma, lymphoma, and solid tumors along with no side effects on different patient profiles, enabling healthcare professionals to treat cancer patients effectively.
Contact Information
Website
www.nkure.comCorporate Office
- Centre for Cellular and Molecular Platforms
- GKVK Post, Bellary Road
- Bangalore, Karnataka 560065
- India
Corporate Office
- Centre for Cellular and Molecular Platforms
- GKVK Post, Bellary Road
- Bangalore, Karnataka 560065
- India
Nkure Therapeutics Timeline
Nkure Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series A) | 03-Nov-2024 | $740K | Completed | Clinical Trials - Phase 1 | ||
| 3. Early Stage VC | 19-Oct-2023 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | 31-Mar-2023 | $1.5M | $1.5M | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Nkure Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nkure Therapeutics Patents
Nkure Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240415892-A1 | Method for expansion and maintenance of nk cells for immunotherapy | Pending | 14-Jun-2023 |
Nkure Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nkure Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Endiya Partners | Venture Capital | Minority | ||
| Featherlite Office Systems | Venture Capital | Minority | ||
| Jacesa Investment | Corporation | Minority | ||
| Kotak Alternate Assets Managers | Asset Manager | Minority | ||
| Centre for Cellular And Molecular Platforms | Accelerator/Incubator |
Nkure Therapeutics FAQs
-
When was Nkure Therapeutics founded?
Nkure Therapeutics was founded in 2022.
-
Where is Nkure Therapeutics headquartered?
Nkure Therapeutics is headquartered in Bangalore, India.
-
What is the size of Nkure Therapeutics?
Nkure Therapeutics has 10 total employees.
-
What industry is Nkure Therapeutics in?
Nkure Therapeutics’s primary industry is Drug Discovery.
-
Is Nkure Therapeutics a private or public company?
Nkure Therapeutics is a Private company.
-
What is Nkure Therapeutics’s current revenue?
The current revenue for Nkure Therapeutics is .
-
How much funding has Nkure Therapeutics raised over time?
Nkure Therapeutics has raised $2.36M.
-
Who are Nkure Therapeutics’s investors?
Endiya Partners, Featherlite Office Systems, Jacesa Investment, Kotak Alternate Assets Managers, and Centre for Cellular And Molecular Platforms have invested in Nkure Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
